NCT02399085 · CITED IN SOURCE DOCUMENTS

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2023-10-23

This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Best Objective Response Rate (ORR)

→

outcome · POSTED

Duration of Response (DoR) by IRC Evaluation

→

outcome · POSTED

DoR by Investigator (INV) Evaluation

→

outcome · POSTED

Progression-free Survival (PFS) by IRC Evaluation

→

outcome · POSTED

PFS by INV Evaluation

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Disease Control Rate (DCR) by IRC Evaluation

→

outcome · POSTED

DCR by INV Evaluation

→

outcome · POSTED

Time to Progression (TTP) by IRC Evaluation

→

outcome · POSTED

TTP by INV Evaluation

→

outcome · POSTED

Time to Next Treatment (TTNT)

→

outcome · POSTED

Event-free Survival (EFS) by IRC Evaluation

→

outcome · POSTED

Serum Drug Levels of MOR00208

→

outcome · POSTED

Number of Participants Who Developed Anti-MOR00208 Antibodies

→

outcome · POSTED

Number of Participants That Experienced Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Severity of Treatment-emergent Adverse Events (TEAEs)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Major Inclusion Criteria: 1. Age \>18 years 2. Histologically confirmed diagnosis of DLBCL 3. Tumour tissue for central pathology review and correlative studies had to be provided. 4. Participants must had: * relapsed and/or refractory disease * at least one bidimensionally measurable, PET positive disease site (transverse diameter of ≥1.5 cm and perpendicular diameter of ≥1.0 cm at baseline) * received at least one, but no more than three previous systemic regimens for the treatment of DLBCL and one therapy line must had included a CD20-targeted therapy * Eastern Cooperative Oncology Group 0 to 2 5. Participants were not considered in the opinion of the investigator eligible, or participants unwilling to undergo intensive salvage therapy including ASCT 6. Participants had to meet the following laboratory criteria at screening: * absolute neutrophil count ≥1.5 × 10˄9/L * platelet count ≥90 × 10˄9/L * total serum bilirubin ≤2.5 × ULN or ≤5 × ULN in cases of Glibert's Syndrome or liver involvement by lymphoma * alanine transaminase, aspartate aminotransferase and alkaline phosphatase ≤3 × ULN or \<5 × ULN in cases of liver involvement * serum creatinine clearance ≥60 mL/minute 7. Females of childbearing potential (FCBP) must: * not be pregnant * refrain from breastfeeding and donating blood or oocytes * agreed to ongoing pregnancy testing * committed to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception 8. Males (if sexually active with a FCBP) had to * use an effective barrier method of contraception * refrain from donating blood or sperm 9. In the opinion of the investigator the participants had to: * be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events * be able to understand, give written informed consent and comply with all study-related procedures, medication use, and evaluations * had no history of noncompliance in relation to medical regimens or not be considered potentially unreliable and/or uncooperative * be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and gave written acknowledgement of this. Major Exclusion Criteria: 1. Participants who had: * other histological type of lymphoma * primary refractory DLBCL * a history of "double/triple hit" genetics 2. Participants who had, within 14 days prior to Day 1 dosing: * not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy * underwent major surgery or suffered from significant traumatic injury * received live vaccines. * required parenteral antimicrobial therapy for active, intercurrent infections 3. Participants who: * had, in the opinion of the investigator, not recovered sufficiently from the adverse toxic effects of prior therapies * were previously treated with CD19-targeted therapy or immunomodulatory drugs (IMiDs)® (e.g., thalidomide, LEN) * had a history of hypersensitivity to compounds of similar biological or chemical composition to MOR00208, IMiDs® and/or the excipients contained in the study drug formulations * had undergone ASCT within the period ≤ 3 months prior to the signing of the Informed Consent Form. Patients who had a more distant history of ASCT had to exhibit full haematological recovery before enrolment into the study * had undergone previous allogenic stem cell transplantation * had a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or were at a high risk for a thromboembolic event in the opinion of the investigator and who were not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period * concurrently used other anti-cancer or experimental treatments 4. Prior history of malignancies other than DLBCL, unless the participant had been free of the disease for ≥5 years prior to screening. 5. Participants with: * positive hepatitis B and/or C serology. * known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV) * CNS lymphoma involvement * history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromised the participant's ability to give informed consent.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
MOR00208: MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle. Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle. LEN: Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings. On days when both study drugs were given together, LEN was administered prior to MOR00208.
intervention Names
Drug: Tafasitamab
Drug: Lenalidomide
label
Tafasitamab (MOR00208) + lenalidomide (LEN)
type
EXPERIMENTAL

interventions

arm Group Labels
Tafasitamab (MOR00208) + lenalidomide (LEN)
description
12 mg/kg
name
Tafasitamab
other Names
MOR00208
type
DRUG
arm Group Labels
Tafasitamab (MOR00208) + lenalidomide (LEN)
description
25 mg
name
Lenalidomide
other Names
LEN
Revlimid®
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 81
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
ORR = complete response \[CR\] + partial response \[PR\]; Independent Radiology/Clinical Review Committee (IRC) Evaluation. ORR after MOR00208 and Lenalidomide combination therapy assessed by the IRC evaluation. ORR was defined as the number of participants of the total number of participants treated with MOR00208 + LEN with CR or PR as best response achieved at any time during the study.
measure
Number of Participants With Best Objective Response Rate (ORR)
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled

secondary Outcomes

description
DoR \[months\] = (date of assessment of tumor progression or death - date of assessment of first documented response of (CR or PR) + 1)/30.4375.
measure
Duration of Response (DoR) by IRC Evaluation
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
DoR \[months\] = (date of assessment of tumour progression or death - date of assessment of first documented response of (CR or PR) + 1)/30.4375.
measure
DoR by Investigator (INV) Evaluation
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
PFS time was defined as the time (in months) from the date of the first administration of any study drug to the date of tumor progression or death from any cause.
measure
Progression-free Survival (PFS) by IRC Evaluation
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
PFS time was defined as the time (in months) from the date of the first administration of any study drug to the date of tumor progression or death from any cause.
measure
PFS by INV Evaluation
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
OS was defined as the time from the date of the first administration of any study drug until death from any cause (documented by the date of death).
measure
Overall Survival (OS)
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
DCR = CR + PR + SD (Stable disease); IRC Evaluation DCR was defined as the number of participants having CR, PR or SD based on the best objective response achieved at any time during the study.
measure
Disease Control Rate (DCR) by IRC Evaluation
time Frame
Approximately 2.5 years after first participant enrolled
description
DCR = CR + PR + SD (Stable disease); IRC Evaluation DCR was defined as the number of participants having CR, PR or SD based on the best objective response achieved at any time during the study.
measure
DCR by INV Evaluation
time Frame
Approximately 2.5 years after first participant enrolled
description
TTP is defined as the time from the first administration of any study drug until documented DLBCL progression or death as a result of lymphoma.
measure
Time to Progression (TTP) by IRC Evaluation
time Frame
Approximately 2.5 years after first participant enrolled
description
TTP is defined as the time from the first administration of any study drug until documented DLBCL progression or death as a result of lymphoma.
measure
TTP by INV Evaluation
time Frame
Approximately 2.5 years after first participant enrolled
description
Kaplan-Meier analysis of TTNT in FAS population. TTNT is defined as the time from the first administration of any study drug to the institution of next anti-neoplastic therapy (for any reason including disease progression, treatment toxicity and participant preference) or death of any cause, whatever comes first.
measure
Time to Next Treatment (TTNT)
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
EFS is defined as the time (in months) from the date of the first administration of any study drug to the date of tumour progression, first initiation of a new non-study anti-neoplastic therapy or death from any cause whichever comes first.
measure
Event-free Survival (EFS) by IRC Evaluation
time Frame
Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled
description
The pharmacokinetics (PK) profile of MOR00208 was investigated by quantifying serum drug levels at baseline and after repeated IV administrations for up to 24 treatment cycles using sparse sampling. MOR00208 PK sample was taken pre-dose and 1 hour ± 10 min after the end of MOR00208 infusion for Cycle 1 to Cycle 23. MOR00208 PK sample (pre-dose only) were taken in odd numbered additional treatment cycles only (e.g., treatment Cycles 13, 15,17, 19, 21, 23).
measure
Serum Drug Levels of MOR00208
time Frame
Cycle 1 Days 1, 4, 15 predose and 1 hr post-dose; Cycle 2 Days 1, 15 predose and 1 hr post-dose; Cycle 3 Days 1, 15 predose and 1 hr post-dose; Cycles 4, 5, 6, 7, 9, 11,13, 15, 17, 19, 21, 23 Day 1 predose; End of Treatment

Full study description

brief Summary: This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).
detailed Description: The aim of this single-arm, multicentre, open-label Phase II study is to evaluate the Lenalidomide (LEN) combined with Tafasitamab (MOR00208) in adult participants with DLBCL who had relapsed after or were refractory to at least one, but no more than three previous systemic regimens administered for the treatment of their DLBCL and who were not candidates for high-dose chemotherapy and subsequent Autologous stem cell transplants and were thus considered to have exhausted their therapeutic options. One prior therapy line had to include an anti-CD20 targeted therapy (e.g., rituximab \[RTX\]). MOR00208 and LEN were administered for up to 12 cycles (28 days each), followed by MOR00208 monotherapy until progression, in participants with at least stable disease or a better response.

Source references

references

citation
Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
pmid
32511983
type
RESULT
citation
Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, Andre M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
pmid
34196165
type
RESULT
citation
Duell J, Obr A, Augustin M, Endell J, Liu H, Geiger S, Silverman IM, Ambarkhane S, Rosenwald A. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leuk Lymphoma. 2022 Feb;63(2):468-472. doi: 10.1080/10428194.2021.1986219. Epub 2021 Nov 15. No abstract available.
pmid
34779360
type
RESULT
citation
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica. 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480.
pmid
37646664
type
DERIVED
citation
Cherng HJ, Westin JR. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls. Clin Cancer Res. 2022 Sep 15;28(18):3908-3910. doi: 10.1158/1078-0432.CCR-22-1626.
pmid
35861632
type
DERIVED
citation
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.
pmid
35674661
type
DERIVED
citation
Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Fowler NH, Salles G, Feinberg B, Kurukulasuriya NC, Tillmanns S, Parche S, Dey D, Fingerle-Rowson G, Ambarkhane S, Winderlich M, Nowakowski GS. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2021 Nov 15;27(22):6124-6134. doi: 10.1158/1078-0432.CCR-21-1471. Epub 2021 Aug 25.
pmid
34433649
type
DERIVED